

Diagnosis & staging

28,229

people were
diagnosed with kidney
cancer in 2019 - 2021

58%

of people with kidney cancer
were diagnosed at stage T1
and any N/M category

21%

of people had metastases

69

years

age at diagnosis
(median)
Interquartile range
59 - 77 years

64%

of people were male

82%

of people with kidney
cancer had a **multi-
disciplinary team meeting
recorded***



2%

of people with kidney
cancer had **consented for a
clinical trial**

*Data completeness measure

Treatment Allocation

20%

of people with a small renal
mass had a biopsy



69%

of people with a T3+ or 10cm+ or N1 and
M0 Renal Cell Carcinoma (RCC) had
**radical nephrectomy within 31 days of
decision to treat.**



Surgery

76%

of people with T1b-3NxM0 RCC
underwent surgery



67%

of people with T1aN0M0 underwent
nephron sparing treatment



Systemic Anti-Cancer Therapy (SACT)

48%

of people with metastatic RCC received initial
SACT within 12 months of diagnosis



3%

of people with kidney cancer
died within 30 days of SACT
treatment



T3+ and/or 10cm+ and/or N1 and M0 RCC - Tumour extends into major veins or perinephric tissues or invades beyond Gerota fascia and/or tumour more than 10cm in size and/or metastasis in regional lymph node(s)

T1b-3NxM0 RCC - Tumour is more than 4cm in size or tumour extends into major veins or perinephric tissues with no distant metastasis

T1aN0M0 RCC - Tumour is less than or equal to 4cm in size with no regional lymph node metastasis and no distant metastasis

Diagnosis & staging

490

people were
diagnosed with kidney
cancer in 2022

46%

of people with kidney cancer
were diagnosed at stage T1
and any N/M category

21%

of people had metastases

70
years

age at diagnosis
(median)
Interquartile range
60 - 78 years

65%

of people were male

99%

of people with kidney
cancer had a **multi-
disciplinary team
meeting recorded***




*Data completeness measure

Treatment Allocation

80%



of people with T2-3NxM0
Renal Cell Carcinoma (RCC)
underwent surgery



Systemic Anti-Cancer Therapy (SACT)


57%

of people with metastatic RCC
received initial SACT within 12
months of diagnosis



3%

of people with kidney cancer
died within 30 days of SACT
treatment



T3+ and/or 10cm+ and/or N1 and M0 RCC - Tumour extends into major veins or perinephric tissues or invades beyond Gerota fascia and/or tumour more than 10cm in size and/or metastasis in regional lymph node(s)

T2-3NxM0 RCC - Tumour is more than 7cm in size or tumour extends into major veins or perinephric tissues with no distant metastasis

T1aN0M0 RCC - Tumour is less than or equal to 4cm in size with no regional lymph node metastasis and no distant metastasis